NCT03256838 - Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis | Biotech Hunter

Enrollment

202

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

May 31, 2019

Conditions

Kidney Failure, ChronicEnd-stage Renal DiseasePhosphorus Metabolism DisordersHyperphosphatemia

Interventions

DRUG

Ferric Citrate

Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.

Trial Locations (9)

Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei

Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei

Division of Nephrology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei

Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei

Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung

Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital, New Taipei City

Division of Nephrology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung

Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung City